Juvenile Arthritis News

Prescription immunosuppressant use is low during the first year of care among young patients with newly diagnosed systemic lupus erythematosus, while hydroxychloroquine use is prevalent, although not universal, researchers report.

The risk for hospital-diagnosed COVID-19 among patients with autoimmune or immune-mediated disease may depend on age, specific disease and prior therapy, according to data published in the Annals of the Rheumatic Diseases.

In a survey of adult and pediatric rheumatologists, 73% reported that they view Down syndrome-associated arthritis as the same disease as juvenile idiopathic arthritis, with 94% stating they use NSAIDs as treatment, according to findings published in Pediatric Rheumatology.

Treatment with canakinumab resulted in rapid, sustained improvements in active systemic juvenile idiopathic arthritis, regardless of whether the patient had a fever at initiation, according to data published in Arthritis & Rheumatology.

A quotidian fever lasting at least 2 weeks is one of the hallmarks of systemic onset juvenile idiopathic arthritis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.

Performing basic clinical observation on patients with temporomandibular joint arthritis is critical to determining whether their disease has improved, worsened or remained the same, according to the Rheumatology Nurses Society president.

Patients with juvenile idiopathic arthritis are more likely to develop concurrent autoimmune disease than those with attention deficit hyperactivity disorder, according to data published in Pediatric Rheumatology.

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.

An estimated 2.95 million children and young people worldwide live with clubfoot, juvenile idiopathic arthritis or juvenile systemic lupus erythematosus, with the greatest prevalence in South Asia, researchers reported.

A U.S. appeals court has ruled in favor of two patents for Amgen’s etanercept against the biosimilar etanercept-szzs from Novartis’ Sandoz, upholding a prior decision validating claims of patent infringement.